Aclaris Therapeutics, Inc.(ACRS)Earnings, Financials & Key RatiosAclaris Therapeutics, Inc. (ACRS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's cash position of $28.7M is insufficient to sustain its current quarterly operating loss of $22.2M, signaling significant liquidity risk for shareholders.
Aclaris Therapeutics, Inc. (ACRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Aclaris Therapeutics, Inc. (ACRS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.15vs $0.16+6.3% | $2Mvs $1M+51.0% |
| Q1 2026 | Feb 26, 2026 | $0.16vs $0.15-6.7% | $1Mvs $2M-37.5% |
| Q4 2025 | Nov 6, 2025 | $0.12vs $0.13+7.7% | $3Mvs $2M+59.3% |
| Q3 2025 | Aug 7, 2025 | $0.13vs $0.13+0.0% | $2Mvs $1M+56.2% |
Recent stock market news and headlines for Aclaris Therapeutics, Inc. (ACRS)
Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
Key metrics vs top competitors for Aclaris Therapeutics, Inc. (ACRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.62 | $677.74M | -10.60 | -58.19% | -829.58% | -50.2% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $140.85 | $9.06B | -68.71 | -89.41% | -648.27% | -17.76% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $6.75 | $185.63M | -14.35 | 10.2% | -14.82% | -35.57% | — |
Aclaris Therapeutics, Inc. (ACRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Aclaris Therapeutics, Inc. (ACRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Apr 28, 2026·SEC
Mar 11, 2026·SEC
Get notified when ACRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aclaris Therapeutics, Inc. (ACRS) stock FAQ — growth, dividends, profitability & financials explained
Aclaris Therapeutics, Inc. (ACRS) reported $8.4M in revenue for fiscal year 2025.
Aclaris Therapeutics, Inc. (ACRS) saw revenue decline by 58.2% over the past year.
Aclaris Therapeutics, Inc. (ACRS) reported a net loss of $69.7M for fiscal year 2025.
Aclaris Therapeutics, Inc. (ACRS) has a return on equity (ROE) of -50.2%. Negative ROE indicates the company is unprofitable.
Aclaris Therapeutics, Inc. (ACRS) had negative free cash flow of $52.3M in fiscal year 2025, likely due to heavy capital investments.
